Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib or Cediranib in Metastatic Alveolar Soft Part Sarcoma
NCT01391962Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2011
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cediranib and sunitinib in alveolar soft part sarcoma (ASPS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 16 months. Started Jul 2011; status: completed.
02
Drugs
cediranibsunitinib
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT01391962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01391962.